Show simple item record

CRISPR-Cas y su aplicación sobre un modelo de Adenovirus como alternativa terapéutica para la resolución de la LMC

dc.contributor.advisorLòpez Lopez, Yalile Ibeth
dc.contributor.authorQuintero Pineda, Paula Daniela
dc.date.accessioned2024-05-21T16:16:41Z
dc.date.available2024-05-21T16:16:41Z
dc.date.issued2021-10
dc.identifier.urihttps://repositorio.universidadmayor.edu.co/handle/unicolmayor/6890
dc.description.abstractLa tecnología CRISPR-Cas fué descubierta por primera vez en S. pyogenes y corresponde a un sistema de defensa que poseen las bacterias contra los fagos y plásmidos; recientes investigaciones apuntan diferentes miras y alcances que posee esta herramienta en materia de edición génica. Sumado a esto, en revisiones actuales se ha demostrado que la terapia viral oncolítica juega cada vez más un rol importante en la resolución tanto de tumores sólidos como de malignidades hematológicas como lo es la leucemia mieloide crónica (LMC). Es por ello, que esta revisión busca definir como alternativa terapéutica a los casos de frecuente recaída, la implementación de un modelo de Adenovirus genéticamente modificado por la tecnología CRISPR-Cas como posible alternativa terapéutica para la resolución de la LMC dentro del marco del análisis documental.spa
dc.description.abstractCRISPR-Cas technology was discovered for the first time in S. pyogenes and is a defense system that bacteria have against phages and plasmids; Recent research points to different perspectives and scope of this tool in terms of gene editing. In addition to this, current reviews have shown 10 that oncolytic viral therapy plays an increasingly important role in the resolution of both solid tumors and hematological malignancies such as chronic myeloid leukemia (CML). For this reason, this review seeks to define as a therapeutic alternative to cases of relapse frequency, the implementation of a genetically modified Adenovirus model by CRISPR-Cas technology as a possible therapeutic alternative for the resolution of CML within the framework of the documentary analysis.eng
dc.description.tableofcontentsTabla de contenido 1. Resumen. 8 Glosario 9 2. Introducción. 12 3. Antecedentes. 14 4. Objetivos. 21 5. Diseño metodológico. 22 6. Marco referencial 23 6.1.1 Beneficios de la tecnología CRISPR-Cas. 24 6.1.2 Tecnología CRISPR-Cas en el siglo de la edición génica. 24 6.2 Adenovirus serotipo 5/52s. 25 6.2.1 Ligandos asociados a la partícula viral. 25 6.2.2 Patogenicidad y su implementación como modelo de terapia viral oncolítica. 26 6.2.3 Beneficios y ventajas de la terapia viral oncolítica. 28 6.2.4 Secuencias Knockout objetivo. 29 6.2.5 Alternativas para reducir la inmunogenicidad contra el modelo viral. 30 6.2.6 Ventajas del modelo Ad5/52s como terapia viral oncolítica sobre las demás alternativas terapéuticas existentes. 31 6.2.7 Otros modelos de terapia viral oncolítica. 31 6.3 Leucemia mieloide crónica 32 6.3.1 Generalidades y mutaciones genéticas implicadas. 33 6.3.2 Ruta diagnóstica. 35 6.3.3 Tratamientos convencionales disponibles. 35 6.3.3.1 Inhibidores de tirosina kinasa (ITK). 36 6.3.3.2 Terapia con interferón. 37 6.3.3.3 Radioterapia. 39 6.3.3.4 Trasplante de médula ósea. 40 6.3.4 Seguimiento al tratamiento en pacientes con LMC. 42 6 6.3.5 Marcadores conocidos de las células madre de la LMC. 42 6.3.5.1 Objetivos terapéuticos. 43 6.3.5.2 Papel de la proteína de choque térmico Hsp27, ADAR1 y GATA-1 en la supervivencia y proliferación celular. 44 6.3.5.3 Características de las secuencias Knockin para escindir sobre Hsp27, GATA-1 y ADAR1. 45 6.3.5.4 Transferencia de información mediada por exosomas. 47 6.3.5.4.1 Ventajas del uso de exosomas. 48 7. Análisis de la información encontrada. 49 7.1 Compilación y contraste de las alternativas terapéuticas disponibles y el modelo viral descrito. 49 7.2 Knockout génico del vector viral: construcción de la herramienta CRISPR-Cas 50 7.3 Knockin del vector viral: construcción teórica de plásmidos recombinantes. 51 7.4 Modelado del genoma viral resultante de la edición génica por CRISPR-Cas9. 52 7.5 Importancia relativa de las revistas compiladas: clasificación por cuartiles. 53 7.6 Importancia mundial de las malignidades hematológicas en el desarrollo investigativo. 53 7.7 Avances científicos orientados a las malignidades hematológicas a lo largo de los años. 55 8. Conclusiones 55 9. Discusión. 60spa
dc.format.extent82p.spa
dc.format.mimetypeapplication/pdfspa
dc.language.isospaspa
dc.publisherUniversidad Colegio Mayor de Cundinamarcaspa
dc.rightsDerechos Reservados - Universidad Colegio Mayor de Cundinamarca, 2024spa
dc.rights.urihttps://creativecommons.org/licenses/by-nc/4.0/spa
dc.titleCRISPR-Cas y su aplicación sobre un modelo de Adenovirus como alternativa terapéutica para la resolución de la LMCspa
dc.typeTrabajo de grado - Pregradospa
dc.contributor.corporatenameUniversidad Colegio Mayor de Cundinamarcaspa
dc.description.degreelevelPregradospa
dc.description.degreenameBacteriólogo(a) y Laboratorista Clínicospa
dc.publisher.facultyFacultad de Ciencias de la Saludspa
dc.publisher.placeBogotá D.Cspa
dc.publisher.programBacteriología y Laboratorio Clínicospa
dc.relation.referencesPettersson U. Structural and Nonstructural Adenovirus Proteins.SpringerLink. [Internet].1984. [citado 4 sep 2020]. Available in: https://link.springer.com/chapter/10.1007/978-1-4684-7935-5_6spa
dc.relation.referencesO'Dell T, Kandel E, & Grant S. Long-term potentiation in the hippocampus is blocked by tyrosine kinase inhibitors. Nature. [Internet]. 1991. [citado 4 sep 2020]. Available in: https://www.nature.com/articles/353558a0spa
dc.relation.referencesVergara C, Martínez C. Las moléculas de adhesión y la respuesta inmune. Revista biomédica. [Internet].1994. [citado 4 sep 2020]. Disponible en: file:///C:/Users/COMPAC%20PRESARIO/Downloads/2101-Texto%20del%20manuscrito%20co mpleto%20(cuadros%20y%20figuras%20insertos)-7677-1-10-20130829.pdf 4.spa
dc.relation.referencesTraycoff C, Srour E, Dutt P, Cornetta F. The 30/35 kDa chymotryptic fragment of fibronectin enhances retroviral-mediated gene transfer in purified chronic myelogenous leukemia bone marrow progenitors. Nature. [Internet]. 1997. [Cited 09 jul 2021]. Available in: https://www.nature.com/articles/2400529#author-informationspa
dc.relation.referencesPeltola1 M, Kytta¨la¨A Heinonen O , Rapola J, Paunio T, Revah F. Adenovirus-mediated gene transfer results in decreased lysosomal storage in brain and total correction in liver of aspartylglucosaminuria (AGU) mouse. Nature. [Internet].1998. [citado 4 sep 2020]. Available in: https://www.nature.com/articles/3300740.pdfspa
dc.relation.referencesBoyes J, Byfield p, Nakatani Y, Ogryzko V. Regulation of activity of the transcription factor GATA-1 by acetylation. Nature. [Internet].1998. [citado 4 sep 2020]. Available in: https://www.nature.com/articles/25166spa
dc.relation.referencesGonzalez R, Vereecque R, Wickham T, Vanrumbeke M, Kovesdi I, Bauters F, et al. Increased gene transfer in acute myeloid leukemic cells by an adenovirus vector containing a modified fiber protein. Nature. [Internet]. 1999. [Cited 09 jul 2021]. Available in: https://www.nature.com/articles/3300836spa
dc.relation.referencesWaller C, Fetscher S, Lange W. Treatment-related chronic myelogenous leukemia. Annals of hematology. [Internet]. 1999. [Cited 09 jul 2021]. Available in: https://link.springer.com/article/10.1007/s002770050527spa
dc.relation.referencesMarini F, Yu Q,Wickham T, Kovesdi I,Andreeff M. Adenovirus as a gene therapy vector for hematopoietic cells. Nature. [Internet]. 1999. [Cited 09 jul 2021]. Available in: https://www.nature.com/articles/7700174spa
dc.relation.referencesFlores J. Leucemia mieloide crónica. Interferón vs transplante de médula ósea. Oncohematología. [Internet]. 2000. [citado 4 sep 2020]. Disponible en: http://www.anmm.org.mx/bgmm/1864_2007/2000-136-SUP2-31-34.pdfspa
dc.relation.referencesMorceau F, Dupont C, Palissot V, Borde-Chiché P, Trentesaux C, Dicato M, Diederich M. GTP-mediated differentiation of the human K562 cell line: transient overexpression of GATA-1 and stabilization of the γ-globin mRNA. Nature. [Internet].2000. [citado 12 sep 2020]. Available in: https://www.nature.com/articles/2401890spa
dc.relation.referencesCheshenko N, Krougliak N, Eisensmith R, Krougliak V. A novel system for the production of fully deleted adenovirus vectors that does not require helper adenovirus. Nature. [Internet].2001. [citado 6 sep 2020]. Available in: https://www.nature.com/articles/3301459#author-informationspa
dc.relation.referencesBernaola G, Luque W. FISIOPATOLOGÍA DE LAS INFECCIONES POR ADENOVIRUS. [Internet] 2002 [citado 20 Abr 2020]. Available in: https://sisbib.unmsm.edu.pe/bvrevistas/paediatrica/v04_n2/fisiopatolog%C3%ADa.htmspa
dc.relation.referencesRosenfeld C, CheeverM, Gaiger A. WT1 in acute leukemia, chronic myelogenous leukemia and myelodysplastic syndrome: therapeutic potential of WT1 targeted therapies. Nature. [Internet]. 2003. [cited 20 Abr 2021]. Avalable in: https://www.nature.com/articles/2402988spa
dc.relation.referencesFernandez F. Estudio secuencial y cuantitativo del quimerismo hemopoyético en pacientes sometidos a un trasplante alogénico de progenitores hemopoyéticos con depleción linfoide T o con acondicionamiento sub-mieloablativo. TDX. [Internet] 2005 [citado 20 Abr 2021]. Disponible en: https://www.tdx.cat/handle/10803/2170#page=1spa
dc.relation.referencesZibert A, Thomassen A, Müller L, Nguyen L, Glouchkova L, Fraefel C, et al. Herpes simplex virus type-1 amplicon vectors for vaccine generation in acute lymphoblastic leukemia. Nature. [Internet]. 2005. [Cited 09 jul 2021]. Available in: https://www.nature.com/articles/3302577#author-informationspa
dc.relation.referencesMartínez F, Orozco j, Fausto A, Villegas C. Biología molecular de los vectores adenovirales. Cirugía y Cirujanos [Internet]. 2006;74(6):483-493. [citado 6 sep 2020]. Disponible en: https://www.redalyc.org/pdf/662/66274613.pdfspa
dc.relation.referencesMassarelli E. KRAS mutation is a predictor of poor response to EGFR tyrosine kinase inhibitors in NSCLC. Nature. [Internet]. 2007. [citado 6 sep 2020]. Available in: https://www.nature.com/articles/ncponc0893spa
dc.relation.referencesZhang W, Cai R, Luo J, Wang Y, Cui Q, Wei X, et al. The oncolytic adenovirus targeting to TERT and RB pathway induced specific and potent anti-tumor efficacy in vitro and in vivo for hepatocellular carcinoma. Cancer Biology and Therapy. [Internet]. 2007. [citado 6 sep 2020]. Available in: https://www.tandfonline.com/doi/abs/10.4161/cbt.6.11.4831 20.spa
dc.relation.referencesQian W, Liu J, Tong Y, Yan S, Yang C, Yang M, et al. Enhanced antitumor activity by a selective conditionally replicating adenovirus combining with MDA-7/interleukin-24 for B-lymphoblastic leukemia via induction of apoptosis. Nature. [Internet]. 2007. [Citado 09 jul 2021]. Available in: https://www.nature.com/articles/2405034#author-informationspa
dc.relation.referencesGarcía J. FACTORES PRONÓSTICO EN LEUCEMIA MIELOIDE CRÓNICA FILADELFIA POSITIVA EN PACIENTES TRATADOS CON INHIBIDORES DE LA TIROSINCINASA [Internet] 2008 [citado 22 mar 2020]. Disponible en: https://hera.ugr.es/tesisugr/17647873.pdfspa
dc.relation.referencesSalazar M. Técnicas para la detección de apoptosis y senescencia celular in vitro y su importancia en biotecnología de la salud. Revista colombiana de biotecnología. [Internet]. 2009. [citado 09 jul 2021]. Disponible en: https://revistas.unal.edu.co/index.php/biotecnologia/article/view/11762spa
dc.relation.referencesIzarzugaza I, Martinez R, Audícana C, Larrañaga N, Hernandez E, Tobalina C, et al. EL CANCER EN EL PAIS VASCO. Vitoria-Gasteiz. [Internet]. 2010 [cited 4 sep 2020]. Disponible en: https://www.osakidetza.euskadi.eus/contenidos/informacion/estado_salud/es_5463/adjuntos/canc er.pdfspa
dc.relation.referencesDe Luca P, Zalazar F, Moiola C, Gueron G, Cotignola J, Vazquez E. RESÚMENES DE LAS COMUNICACIONES. Medicina (Buenos Aires). [Internet]. 2010 [cited 4 sep 2020]. Disponible en: https://eds-a-ebscohost-com.ezproxy.javeriana.edu.co/eds/pdfviewer/pdfviewer?vid=2&sid=fe44 0518-066c-4197-92de-d0f383add989%40sessionmgr4008spa
dc.relation.referencesPoláková K, Lopotová T, Klamová H, Burda P, Trněný M, Stopka T. Expression patterns of microRNAs associated with CML phases and their disease related targets. Springer Link. [Internet].2013. [cited 11 sep 2020]. Available in: https://link.springer.com/article/10.1186/1476-4598-10-41#Abs1spa
dc.relation.referencesSethu S, Govindappa K, Alhaidari M, Pirmohamed M, Park K, Sathish J. Immunogenicity to Biologics: Mechanisms, Prediction and Reduction. SpringerLink. [Internet]. 2012 [cited 4 sep 2020]. Available in: https://link.springer.com/article/10.1007/s00005-012-0189-7spa
dc.relation.referencesXu C, Fu H, Gao L, Wang L,Wang W, Li J. BCR-ABL/GATA1/miR-138 mini circuitry contributes to the leukemogenesis of chronic myeloid leukemia. Nature [Internet]. 2012 [cited 4 sep 2020]. Available in: https://www.nature.com/articles/onc2012557#author-informationspa
dc.relation.referencesVelásquez J, Fonseca D, Jacal M, Sánchez M, Sánchez D, Guerrero S. Diagnóstico citogenético y seguimiento molecular en la leucemia mieloide crónica. Esp Méd Quir. [Internet].2013. [citado 11 sep 2020].disponible en: https://www.medigraphic.com/pdfs/quirurgicas/rmq-2013/rmq133o.pdfspa
dc.relation.referencesYang Y, Xiao F, Lu Z, Li Z, Zuo H, Zhang Q, et al. Development of a novel adenovirus–alphavirus hybrid vector with RNA replicon features for malignant hematopoietic cell transduction. Nature. [Internet]. 2013. [cited 09 jul 2021]. Available in: https://www.nature.com/articles/cgt201337spa
dc.relation.referencesMellier G, Liu D, Bellot G, Holme A, Pervaiz S. Small molecule sensitization to TRAIL is mediated via nuclear localization, phosphorylation and inhibition of chaperone activity of Hsp27. Nature. [Internet].2013. [cited 11 sep 2020]. Available in: https://www.nature.com/articles/cddis2013413spa
dc.relation.referencesOrganización mundial de la salud. Perfiles oncológicos de los países. OMS. [Internet] 2014 [citado 20 Abr 2020].Disponible en: https://www.who.int/cancer/country-profiles/col_es.pdf?ua=1spa
dc.relation.referencesNature. Genome editing for all. [Internet] 2014 [citado 20 Abr 2020]. Available in: https://www.nature.com/articles/nbt.2879spa
dc.relation.referencesYoshimi K, Kaneko T, Voigt B, Mashimo T. Allele-specific genome editing and correction of disease-associated phenotypes in rats using the CRISPR–Cas platform. Nature. [Internet]. 2014 [cited 20 mar 2020]. Available in: https://www.nature.com/articles/ncomms5240#Sec6spa
dc.relation.referencesBoyiadzis M, Whiteside L. Information transfer by exosomes: A new frontier in hematologic malignancies. Sciencedirect [Internet]. 2015 [cited 20 mar 2020]. Available in: https://www.sciencedirect.com/science/article/abs/pii/S0268960X15000132?via%3Dihubspa
dc.relation.referencesParrish C, Scott B, Migneco G, Scott J, Steele P, Ilett E, et al. Oncolytic reovirus enhances rituximab-mediated antibody-dependent cellular cytotoxicity against chronic lymphocytic leukaemia. Nature [Internet]. 2015. [cited 9 jul 2021]. Available in: https://www.nature.com/articles/leu201588#author-informationspa
dc.relation.referencesLi H, Hui H, Xu J, Yang H, Zhang X, Liu X, et al. Wogonoside induces growth inhibition and cell cycle arrest via promoting the expression and binding activity of GATA-1 in chronic myelogenous leukemia cells. SpringerLink [Internet]. 2015 [cited 20 mar 2020]. Available in: https://link.springer.com/article/10.1007/s00204-015-1552-3spa
dc.relation.referencesNaka k, Jomen Y, Ishihara K, Kim J, Ishimoto T, Bae E, et al. Dipeptide species regulate p38MAPK–Smad3 signalling to maintain chronic myelogenous leukaemia stem cells. Nature [Internet]. 2015 [cited 20 mar 2020]. Available in: https://www.nature.com/articles/ncomms9039spa
dc.relation.referencesGarcia M. GENERACIÓN DE UN ADENOVIRUS QUIMÉRICO AD5/52s PSEUDOTIPADO CON LA PROTEÍNA FIBER CORTA DEL Ad52 PARA SU CARACTERIZACIÓN IN VITRO E IN VIVO COMO VECTOR DE TERAPIA GÉNICA. [Internet]. 2015 [citado 19 sep 2020]. Disponible en: https://ddd.uab.cat/pub/tesis/2016/hdl_10803_370116/mgm1de1.pdfspa
dc.relation.referencesMojica F. “Sistemas CRISPR-Cas, una revolución biotecnológica con origen bacteriano”. [Internet]. 2016 [cited 18 mar 2020]. Disponible en: https://www.youtube.com/watch?v=GOK6FkfmHdQspa
dc.relation.referencesWu B, Ingersoll K, Rehder C, Wang S. Sequential development of chronic myelogenous leukemia and primary myelofibrosis in a patient with history of large B-cell lymphoma treated with radiotherapy and chemotherapy: two myeloid neoplasms with distinct genotypic profiles suggestive of biclonality in a single individual. Annals of hematology. [Internet]. 2016. [cited 9 jul 2021]. Available in: https://link.springer.com/article/10.1007/s00277-016-2707-xspa
dc.relation.referencesAbyntek. INTRODUCCIÓN A LA TECNOLOGÍA CRISPR-CAS 9. [Internet]. 2016 [cited 18 mar 2020]. Disponible en: https://www.abyntek.com/introduccion-a-la-tecnologia-crispr/spa
dc.relation.referencesGonzalez S. La donación de médula ósea, influenciada por su desconocimiento. [Internet]. 2016 [cited 18 mar 2020]. Disponible en: http://tauja.ujaen.es/bitstream/10953.1/3712/1/TFG_Sergio_Gonzlez_Martnez.pdfspa
dc.relation.referencesLaila Y. Bielski, Ana M. Orlandi, Hugo R. Boquete. Inhibidores de tirosina cinasa y disfunción tiroidea. ELSEVIER. [Internet]. 2016 [cited 18 mar 2020]. Disponible en: https://www.elsevier.es/es-revista-revista-argentina-endocrinologia-metabolismo-185-articulo-in hibidores-tirosina-cinasa-disfuncion-tiroidea-S0326461016300511spa
dc.relation.referencesHeinrich J, Donakonda S, Joachim V, Lennig P, Zhang Y, Schroeder M. New HSP27 inhibitors efficiently suppress drug resistance development in cancer cells. Oncotarget. [Internet]. 2016 [cited 18 mar 2020]. Available in: https://www.oncotarget.com/article/11905/spa
dc.relation.referencesLompardía SL, Díaz M, Papademetrio DL, Pibuel M, Álvarez E, Hajos SE. 4-methylumbelliferone and imatinib combination enhances senescence induction in chronic myeloid leukemia cell lines. SpringerLink [Internet]. 2016 [cited 18 mar 2020]. Available in: https://link.springer.com/article/10.1007%2Fs10637-016-0397-9spa
dc.relation.referencesSmirnova O. Radiogenic Leukemia Risk Assessment. [Internet]. 2016. [cited 09 jul 2021]. Available in: https://link.springer.com/chapter/10.1007/978-3-319-45761-1_8spa
dc.relation.referencesWan T. Cancer Cytogenetics: An Introduction. SpringerLink [Internet]. 2016 [cited 18 mar 2020]. Available in: https://link.springer.com/protocol/10.1007%2F978-1-4939-6703-2_1spa
dc.relation.referencesBengio L, Enrico R, Freitas A, Larripa J, Pavlovsky I, Riveros M, et al. Leucemia mieloide crónica. Sociedad argentina de hematología. [Internet]. 2017 [citado 18 mar 2020]. Disponible en: http://sah.org.ar/docs/2017/008-Leucemia%20Mieloide%20Cr%C3%B3nica.pdfspa
dc.relation.referencesOrganización mundial de la salud. Probióticos y prebióticos. [Internet]. 2017 [citado 18 mar 2020]. Disponible en: https://www.worldgastroenterology.org/UserFiles/file/guidelines/probiotics-and-prebiotics-spanis h-2017.pdfspa
dc.relation.referencesChen Y, Zhou Q, Zhang L, Zhong Y, Fan G, Zhang Z, et al. Stellettin B induces apoptosis in human chronic myeloid leukemia cells via targeting PI3K and Stat5. Oncotarget [Internet]. 2017 [cited 18 mar 2020]. Available in: https://www.oncotarget.com/index.php?journal=oncotarget&page=article&op=view&path%5b% 5d=15957&pubmed-linkout=1spa
dc.relation.referencesWan, Thomas S. Cancer cytogenetics methods and protocols. SpringerLink. [Internet]. 2017 [cited 18 mar 2020]. Available in: https://www.springer.com/gp/book/9781493967018spa
dc.relation.referencesLiang X, Potter J, Kumar S, Ravinder N, Chesnut J. Enhanced CRISPR/Cas9-mediated precise genome editing by improved design and delivery of gRNA, Cas9 nuclease, and donor DNA. Journal of biotechnology. [Internet]. 2017. [cited 09 jul 2021]. Available in: https://www.sciencedirect.com/science/article/pii/S016816561631611X?via%3Dihubspa
dc.relation.referencesBoyiadzis M, Whiteside L. The emerging roles of tumor-derived exosomes in hematological malignancies. Nature. [Internet]. 2017. [cited 18 mar 2020]. Available in: https://www.nature.com/articles/leu201791spa
dc.relation.referencesBengio R, Enrico A, Moiraghi B. Leucemia mieloide crónica. HEMATOLOGÍA. [Internet]. 2017 [cited 18 mar 2020]. Disponible en: http://sah.org.ar/docs/203-230.4.SAH_GUIA2012_LeucemiaCronica.pdfspa
dc.relation.referencesLi L, You L, Mao L, Jin S, Chen X, Qian W. Combing oncolytic adenovirus expressing Beclin-1 with chemotherapy agent doxorubicin synergistically enhances cytotoxicity in human CML cells in vitro [Internet]. 2017 [Cited 18 mar 2020]. Available in: https://www.nature.com/articles/aps2017100#Abs1spa
dc.relation.referencesLY303511.1 KR 1020160079864-A/4030: OPTIMAL SOYBEAN LOCI. NIH [Internet]. 2017 [citado 11 sep 2020]. Disponible en: https://www.ncbi.nlm.nih.gov/nuccore/LY303511spa
dc.relation.referencesBianchini M. Biología de la leucemia mieloide crónica. Hematología [Internet]. 2017 [citado 20 mar 2020]. Disponible en: http://www.sah.org.ar/revista/numeros/vol21/extra3/38-vol21-extra_noviembre.pdf 77spa
dc.relation.referencesWhiteside L. The effect of tumor-derived exosomes on immune regulation and cancer immunotherapy. NIH. [Internet]. 2017 [citado 20 mar 2020]. Available in: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5827821/spa
dc.relation.referencesSarmiento D, Ruiz A. EVENTOS ADVERSOS Y PROBLEMAS RELACIONADOS CON MEDICAMENTOS INTERFERONES REPORTADOS EN BOGOTÁ D.C. 2008 – 2017. [Internet]. 2018 [citado 19 sep 2020]. Disponible en: https://repository.udca.edu.co/bitstream/11158/1003/1/TRABAJO%20DE%20GRADO%20INTE RFERONES.pdfspa
dc.relation.referencesGuerrero R. Caracterización del potencial oncolítico del aislamiento rotaviral Wt1-5 en cultivos primarios de leucemia linfoblástica aguda de precursores B. [Internet]. 2018 [citado 19 sep 2020]. Disponible en: file:///C:/Users/COMPAC%20PRESARIO/Downloads/1049605017.2018.pdfspa
dc.relation.referencesHu H, Miller S, Geurts M, Tang W, Chen L, Sun N, et al. Evolved Cas9 variants with broad PAM compatibility and high DNA specificity. Nature. [Internet]. 2018. [cited 09 jul 2021]. Available in: https://www.nature.com/articles/nature26155#author-informationspa
dc.relation.referencesPalacio G, Ramirez G, Muskus C, Torres J, Aya C. Detección de mutaciones en el dominio tirosina quinasa de BCR-ABL1 en pacientes colombianos con leucemia mieloide crónica LMC, resistentes al imatinib. ELSEVIER [Internet]. 2018 [citado 19 sep 2020]. Disponible en: https://www.elsevier.es/es-revista-revista-colombiana-cancerologia-361-articulo-deteccion-mutac iones-el-dominio-tirosina-S0123901518300210spa
dc.relation.referencesTeepen C, Curtis R, Dores G, Gonzalez A, Eibrink M, Kremer L. Risk of subsequent myeloid neoplasms after radiotherapy treatment for a solid cancer among adults in the United States, 2000–2014. Nature. [Internet]. 2018. [cited 09 jul 2021]. Available in: https://www.nature.com/articles/s41375-018-0149-2spa
dc.relation.referencesAmerican Cancer Society.Trasplante de células madre para la leucemia mieloide crónica. [Internet]. 2018 [citado 19 sep 2020]. Disponible en: https://www.cancer.org/es/cancer/leucemia-mieloide-cronica/tratamiento/celulas-madre-de-la-me dula-osea.htmlspa
dc.relation.referencesPinheiro T, Feitosa M, Santos M, Saraiva R, Longatti S. DIAGNÓSTICO LABORATORIAL DA LEUCEMIA MIELOIDE CRÔNICA. Revista de Medicina e Saúde de Brasília [Internet] 2018 [acima mencionado 6 sep 2020]. Disponível em: https://eds-b-ebscohost-com.ezproxy.javeriana.edu.co/eds/pdfviewer/pdfviewer?vid=2&sid=c81d e0f6-c4e1-4334-97f7-94367b224e6e%40sessionmgr101spa
dc.relation.referencesNIH. Radioterapia para tratar el cáncer. NIH. [Internet]. 2019 [cited 15 mar 2020]. Disponible en: https://www.cancer.gov/espanol/cancer/tratamiento/tipos/radioterapiaspa
dc.relation.referencesMa L, Pak L, Ou J, Yu J, Louis P, Shan Y, et al. Prosurvival kinase PIM2 is a therapeutic target for eradication of chronic myeloid leukemia stem cells. PNAS [Internet]. 2019 [cited 15 mar 2020]. Available in: https://www.pnas.org/content/116/21/10482spa
dc.relation.referencesTúlich L. Exosomas como sistemas de delivery de drogas. UTEC. [Internet]. 2019. [citado 15 mar 2021]. Disponible en: https://www.utec.edu.pe/blog-de-carreras/bioingenieria/exosomas-como-sistemas-de-delivery-de -drogas#:~:text=Exosomas%20como%20sistema%20de%20administraci%C3%B3n%20terap% C3%A9utica%3A,objetivos%20espec%C3%ADficos%20a%20larga%20distancia.spa
dc.relation.referencesPickar A, Gerbach C. The next generation of CRISPR–Cas technologies and applications. Nature [Internet]. 2019. [cited 15 mar 2020]. Available in: https://www.nature.com/articles/s41580-019-0131-5spa
dc.relation.referencesHu Y, Joo H, Lee K, Kim H, Didier R, Yang Y, et al. Streamlined procedure for gene knockouts using all-in-one adenoviral CRISPR-Cas9. Nature. [Internet] 2019 [cited 15 mar 2020]. Available in: https://www.nature.com/articles/s41598-018-36736-yspa
dc.relation.referencesAbudoureyimu M, Lai Y, Tian C, Wang T, Wang R, Chu X. Oncolytic Adenovirus—A Nova for Gene-Targeted Oncolytic Viral Therapy in HCC. Front Oncol. [Internet] 2019 [cited 15 mar 2020]. Available in: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6857090/spa
dc.relation.referencesRoss Cloney. Gene editing by CRISPR–Cas. Nature. [Internet] 2019 [cited 14 abri 2021]. Available in: https://media.nature.com/original/magazine-assets/d42859-019-00088-y/d42859-019-00088-y.pd fspa
dc.relation.referencesVeiga A. Células Stem mesenquimales en el transplante alogénico de progenitores hematopoyéticos: análisis de la experiencia clínica de la unidad de producción celular del Complejo Asistencial Universitario de Salamanca. [Internet] 2020 [cited 14 abri 2021]. Disponible en: https://gredos.usal.es/bitstream/handle/10366/145442/Veiga%20Vaz%2c%20Alvaro.pdf?sequenc e=1&isAllowed=yspa
dc.relation.referencesSteegmann J, Casado L, Catellano P, Gómez M, Jiménez A, Peréz M, et al. Manual para el control y el tratamiento de los apcientes con leucemia mieloide crónica. GEL-MC. [Internet]. 2020. [Citado 27 marr 2021]. Disponible en: file:///C:/Users/COMPAC%20PRESARIO/Downloads/Manual-GELMC-2020-VDigital.pdfspa
dc.relation.referencesDoudna J. The promise and challenge of therapeutic genome editing. Nature. [Internet] 2020 [cited 15 mar 2020]. Available in: https://www.nature.com/articles/s41586-020-1978-5spa
dc.relation.referencesMatthew C. A Workflow for Knock-in Genome Editing: Simplified. [Internet] 2020 [cited 15 mar 2020]. Available in: https://www.youtube.com/watch?v=Bto_v5au8o4spa
dc.relation.referencesMcCarty N, Graham A, Studená L, Amaro R. Multiplexed CRISPR technologies for gene editing and transcriptional regulation. Nature. [Internet] 2020 [cited 15 mar 2020]. Available in: https://www.nature.com/articles/s41467-020-15053-x#author-informationspa
dc.relation.referencesBajaj J, Hamilton M, Shima Y, Chambers K, Spinler K, Nostrand E, Yee B, et al. An in vivo genome-wide CRISPR screen identifies the RNA-binding protein Staufen2 as a key regulator of myeloid leukemia. Nature. [Internet]. 2020. [cited 09 jul 2021]. Available in: nature.com/articles/s43018-020-0054-2spa
dc.relation.referencesWang Z, Liu W, Wang L, Gao P, Li Z, Wu J, et al. Enhancing the antitumor activity of an engineered TRAIL-coated oncolytic adenovirus for treating acute myeloid leukemia. Nature. [Internet]. 2020. [cited 09 jul 2021]. Available in: https://www.nature.com/articles/s41392-020-0135-9#Sec23spa
dc.relation.referencesAcyrthosiphon pisum clone LLO1 p300 mRNA, partial cds. NIH [Internet]. 2020 [citado 12 sep 2020]. Disponible en: https://www.ncbi.nlm.nih.gov/nuccore/MN734788.1 81. Polakova K, Zizkova H, Zuna J, Motlova E, Hovorkova L, Gottschalk A, et al. Analysis of chronic myeloid leukaemia during deep molecular response by genomic PCR: a traffic lightspa
dc.rights.accessrightsinfo:eu-repo/semantics/closedAccessspa
dc.rights.creativecommonsAtribución-NoComercial 4.0 Internacional (CC BY-NC 4.0)spa
dc.subject.proposalCRISPR-Casspa
dc.subject.proposalTerapia viral oncolíticaspa
dc.subject.proposalLeucemia mieloide crónicaspa
dc.subject.proposalAdenovirusspa
dc.type.coarhttp://purl.org/coar/resource_type/c_7a1fspa
dc.type.coarversionhttp://purl.org/coar/version/c_970fb48d4fbd8a85spa
dc.type.contentTextspa
dc.type.driverinfo:eu-repo/semantics/bachelorThesisspa
dc.type.redcolhttps://purl.org/redcol/resource_type/TPspa
dc.type.versioninfo:eu-repo/semantics/publishedVersionspa
dc.rights.coarhttp://purl.org/coar/access_right/c_14cbspa


Files in this item

Thumbnail
Name:
CRISPR-Cas Y SU APLICACIÓN SOBRE ...
Size:
452.6Kb
Format:
PDF
View/Open
Thumbnail
Name:
CRISPR-Cas Y SU APLICACIÓN SOBRE ...
Size:
12.04Mb
Format:
Microsoft PowerPoint 2007
View/Open
Thumbnail
Name:
FORMATO CARTA DERECHOS DE AUTOR ...
Size:
93.63Kb
Format:
PDF
View/Open
Thumbnail
Name:
1.FORMATO DERECHOS DE AUTOR TG ...
Size:
201.4Kb
Format:
PDF
View/Open

This item appears in the following Collection(s)

Show simple item record

Derechos Reservados - Universidad Colegio Mayor de Cundinamarca, 2024
Except where otherwise noted, this item's license is described as Derechos Reservados - Universidad Colegio Mayor de Cundinamarca, 2024